J&J's (JNJ) and Pfizer' (PFE) bapineuzumab drug showed signs that it is able to reduce...

|By:, SA News Editor

J&J's (JNJ) and Pfizer' (PFE) bapineuzumab drug showed signs that it is able to reduce nerve-cell damage in the brain and the buildup of amyloid plaque, which has been linked to Alzheimer's disease. While bapineuzumab was unable to improve patients' memory or thinking, as disclosed last month, the drug could eventually be used as a preventative measure.